Young but accomplished- that is the best definition anyone can get for Adrangi of Kerrisdale Capital Management. At only 35, he has done what some seasoned hedge fund investors and managers fear to even try their hands on. The company is small regarding size and human resource, but SahmAdrangi manages to stand-in for a handful of professionals. His experience on Wall Street is enough to give legendary financial firms a good run for their money. After going the full cycle from a hedge manager fund manager, to a credit trader, credit portfolio manager, and lastly to a credit analyst, Sahm decided to take a break from active investment life. In his what many would call a sabbatical, he manages his firm- Kerrisdale Capital Management.
Dominating Wall Street
For over a decade working as a hedge fund manager, Adrangi worked with three top-level funds. Among the hedge funds that he managed were Paulson & Co and Longacre hedge fund, with the latter having been worth over $3 billion. As for the former, SahmAdrangi managed to master the art of shorting mortgage bonds, and by the end of his stay there, he had already raised the fund’s worth to over $6 billion. Having achieved all that, he saw it wise to throw the towel into the ring and call it a day. As of whether he will find his way back to Wall Street, it will be his personal decision to make. He, however, has made a good fortune from his role at Kerrisdale Capital Management.
More about Adrangi
In April last year, Adrangi was at it again doing what he does best- doing what is ordinarily considered impossible. He led his team at Kerrisdale Capital in raising over $100 million over a record short time, with the aim of investing in a $10 billion public company later. He developed websites for the company and marketed it far and wide, eventually winning over potential investors.
Adrangi became a professional economist 15 years ago after acquiring his B.A from Yale University. He then spent a couple of his early career days working for Deutsche Bank. Before moving to New York, Adrangi was working in Los Angeles as an analyst for Chanin Capital Partners. Adrangi established his firm in 2009.
SahmAdrangi is an Iranian-born Canadian, founder and the Chief Investment Officer of Kerrisdale Capital Management. SahmAdrangi is a holder of Bachelors of Arts in Economics from the Yale University. At the University, he wrote cavalcades for the campus newspaper which shows his subliminal progression from lefty rabble-rouser.
Before finding his firm, he was an investment analyst at Longacre Fund, which is a private investment partnership. In the firm, he conducted investment analysis and research for both the credit fund and equity fund. He has also worked at Chanin Capital Part in the bankruptcy restructuring group where he gave advice to creditors. His work included representing bondholder committees, bank debt holders, preferred equity committees and creditors of bankrupt companies. He has also worked at Leverage Finance group of Deutsche Bank where his job was to syndicate and structure high yield bonds and non-investment grade bank debt, by buy-out financing, exit financing, and debt refinancing.
Sahm at Kerrisdale Capital Management
In Kerrisdale Capital Management, he has been in charge of all developmental operations. The company was launched with under $1 million but it currently manages $150 million. He is best known for publishing and short-selling research. Besides publishing research, he has been an activist in many investments including Lindsay corporation management. He has been a speaker at several conferences, which includes the Sohn Conference, the distressed debt investing conference, the value investing conference and traders for a cause. He got famous when he first exposed fraudulent Chinese companies, subsuming China-biotics, Lihua international, China Marine Food Group and many others. He has appeared in various interviews on Bloomberg and CNBC where he’s been headlined in major publications including, Washington Post, Wall Street Journal, New York Times, among others.
Adrangi is a fairly recent convert to dog-eat-dog capitalism. While his firm shares research on a wide variety of industries and companies, recently, he has focused the firm’s evolvement on specific sectors where it has refined expertise. One area of focus has been the Biotechnology sector and it has published research on development stage companies which includes Zafgen, Therapeutics, Bavarian Nordic and plentiful others.